Enter your number to get our free mobile app

The Texas Tech University Health Sciences Center Research Team has been awarded a $7.25 million grant for "Medication Development for the Treatment of Alcohol Use Disorder."

Susan Bergeson, Ph.D., a Professor at TTUHSC, is dedicated to understanding the mechanisms surrounding alcohol use disorder (AUD), and recently she and Ted Reid, Ph.D., professor of ophthalmology and visual sciences, designed a new medication that is on the path to approval by the FDA.

The team also includes David Edwards, M.D., the Phase 1 clinical trial leader; Regina Baronia, M.D., and David Trotter, Ph.D., clinical experts in AUD; and Min Kang, Pharm.D., a licensed pharmacist and pharmacologist, Jaehoon Lee, Ph.D., from Texas Tech University, and project consultants include Peter Syapin, Ph.D., TTHUSC professor emeritus, and Adron Harris, Ph.D., and Robert Messing, M.D., from The University of Texas at Austin.

After showing efficacy in mice and swine, this new grant will take the drug through 3 important steps. The first is to develop manufacturing standards. The second is to ensure a potential drug is safe, which is required by the FDA. Then the team will need to present their preclinical animal studies to the FDA for approval prior to carrying out the first phase clinical trial.

Bergeson says that this grant is a good example of the university investing in its researchers and having something valuable to show for it.